Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database

Name: Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database
Creator: Yuanyuan Xu
Published: 2024-07-04T22:09:57.344Z
Keywords: Dermatology

Xu, Yuanyuan; Wu, Shuwei; Guo, Linhong; Jiang, Xian

doi:10.17632/p7g3bspg6x.1

Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database

Published: 4 July 2024| Version 1 | DOI: 10.17632/p7g3bspg6x.1

Contributors:

Yuanyuan Xu, Shuwei Wu, Linhong Guo, Xian Jiang

Description

This data is the supplementary data for a manuscript entitled "Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database. In our study, we revealed the distinct adverse event (AE) profiles of two marketed oral small-molecule drugs, namely apremilast and deucravacitinib.

Adverse events associated with oral small-molecule drugs in the treatment of psoriasis and psoriatic arthritis: a pharmacovigilance study based on the FAERS database

Description

Files

Categories

Licence